EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

Biomedical Reports, published by SPANDIDOS PUBL LTD in Greece, is a distinguished open-access journal that focuses on the dynamic fields of biochemistry, genetics, molecular biology, medicine, pharmacology, and neuroscience. Established in 2014, the journal has rapidly gained recognition, securing Q2 and Q3 rankings in several categories for 2023, including a notable ranking of #125/636 in General Medicine, placing it in the 80th percentile amongst its peers. The journal continually aims to disseminate innovative research findings that advance the understanding of complex biomedical issues, making it an invaluable resource for researchers, professionals, and students alike. Its multidisciplinary approach not only reflects the interconnectivity of modern biomedical sciences but also promotes collaborative discourse among diverse fields, ensuring ongoing relevance and impact within the scientific community.

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

The Journal of Pathology Clinical Research is a prestigious academic platform published by WILEY, dedicated to advancing the field of pathology and forensic medicine. Since its inception in 2015, this Open Access journal has championed the dissemination of cutting-edge research relevant to both clinical practice and laboratory science, allowing for greater visibility and accessibility to researchers, professionals, and students worldwide. With a robust Q1 ranking in the Pathology and Forensic Medicine category for 2023, it stands as a critical resource for those seeking to stay at the forefront of the field, currently positioned at rank #29 out of 208 according to Scopus metrics, placing it in the 86th percentile. The journal's commitment to high-quality peer-reviewed articles fosters an environment of scholarly exchange that is essential for innovation and professional growth in pathology and forensic studies. Researchers and practitioners alike are encouraged to contribute and engage with a community dedicated to excellence in clinical research.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.